GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
-4%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.26B
AUM Growth
-$362M
(-7.8%)
Cap. Flow
-$2.11M
Cap. Flow
% of AUM
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
43.71%
Holding
683
New
46
Increased
475
Reduced
93
Closed
17
Top Buys
| 1 |
Philip Morris
PM
|
$43M |
| 2 |
Amazon
AMZN
|
$24.3M |
| 3 |
Palantir
PLTR
|
$16.8M |
| 4 |
Yum China
YUMC
|
$14.4M |
| 5 |
Hims & Hers Health
HIMS
|
$10.9M |
Top Sells
| 1 |
Pinduoduo
PDD
|
$40.6M |
| 2 |
NVIDIA
NVDA
|
$25.7M |
| 3 |
KE Holdings
BEKE
|
$14.3M |
| 4 |
Meta Platforms (Facebook)
META
|
$13.3M |
| 5 |
Coca-Cola
KO
|
$9.83M |
Sector Composition
| 1 | Technology | 42.51% |
| 2 | Consumer Discretionary | 16.26% |
| 3 | Communication Services | 14.17% |
| 4 | Healthcare | 7.8% |
| 5 | Consumer Staples | 6.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
LXP Industrial Trust
LXP
$2.71B
| $48.3K | ﹤0.01% |
5,578
+229
| +4% | +$1.98K |
|
427
Acadia Realty Trust
AKR
$2.63B
| $47.5K | ﹤0.01% |
2,266
+352
| +18% | +$7.37K |
|
428
Arcutis Biotherapeutics
ARQT
$2.06B
| $46.9K | ﹤0.01% |
2,996
+538
| +22% | +$8.41K |
|
429
Supernus Pharmaceuticals
SUPN
$2.58B
| $46.3K | ﹤0.01% |
1,413
+254
| +22% | +$8.32K |
|
430
Kymera Therapeutics
KYMR
$3.11B
| $45.4K | ﹤0.01% |
1,658
+298
| +22% | +$8.16K |
|
431
Urban Edge Properties
UE
$2.67B
| $44.9K | ﹤0.01% |
2,365
+160
| +7% | +$3.04K |
|
432
Dynavax Technologies
DVAX
$1.18B
| $43.7K | ﹤0.01% |
3,366
+606
| +22% | +$7.86K |
|
|
CURB
433
Curbline Properties Corp.
CURB
$2.41B
| $43.3K | ﹤0.01% |
1,791
+76
| +4% | +$1.84K |
|
434
Apogee Therapeutics
APGE
$2.26B
| $43.1K | ﹤0.01% |
1,153
+208
| +22% | +$7.77K |
|
435
InvenTrust Properties
IVT
$2.33B
| $42.9K | ﹤0.01% |
1,461
+59
| +4% | +$1.73K |
|
436
Agios Pharmaceuticals
AGIO
$2.09B
| $42.8K | ﹤0.01% |
1,460
+263
| +22% | +$7.71K |
|
437
CG Oncology
CGON
$2.52B
| $42.4K | ﹤0.01% |
1,731
+311
| +22% | +$7.62K |
|
438
Park Hotels & Resorts
PK
$2.4B
| $41.9K | ﹤0.01% |
3,919
+123
| +3% | +$1.31K |
|
439
Beam Therapeutics
BEAM
$2.11B
| $41.4K | ﹤0.01% |
2,120
+381
| +22% | +$7.44K |
|
440
Arrowhead Research
ARWR
$4.02B
| $40.6K | ﹤0.01% |
3,186
+573
| +22% | +$7.3K |
|
441
BioCryst Pharmaceuticals
BCRX
$1.74B
| $39.8K | ﹤0.01% |
5,303
+954
| +22% | +$7.16K |
|
442
Travere Therapeutics
TVTX
$1.93B
| $39.4K | ﹤0.01% |
2,198
+395
| +22% | +$7.08K |
|
443
Vera Therapeutics
VERA
$1.54B
| $38.9K | ﹤0.01% |
1,621
+291
| +22% | +$6.99K |
|
444
Disc Medicine
IRON
$2.11B
| $37.8K | ﹤0.01% |
762
+137
| +22% | +$6.8K |
|
445
Janux Therapeutics
JANX
$1.44B
| $36.3K | ﹤0.01% |
1,343
+241
| +22% | +$6.51K |
|
446
IDEAYA Biosciences
IDYA
$2.38B
| $36.2K | ﹤0.01% |
2,213
+398
| +22% | +$6.52K |
|
447
ANI Pharmaceuticals
ANIP
$2.07B
| $36K | ﹤0.01% |
538
+97
| +22% | +$6.49K |
|
448
Amphastar Pharmaceuticals
AMPH
$1.37B
| $35.7K | ﹤0.01% |
1,230
+220
| +22% | +$6.38K |
|
449
MannKind Corp
MNKD
$1.7B
| $35.5K | ﹤0.01% |
7,061
+1,270
| +22% | +$6.39K |
|
450
Sunstone Hotel Investors
SHO
$1.81B
| $34.1K | ﹤0.01% |
3,624
+114
| +3% | +$1.07K |
|